DM
DMAC.US DiaMedica Therapeutics Inc
- Market cap
- USD 474M
- P/E
- -
- P/B
- 13.14x
- ROE
- -146.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DMAC.US undervalued?
Graham numberThe Graham number of DiaMedica Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DiaMedica Therapeutics Inc fundamental analysis
No fundamental analysis for DiaMedica Therapeutics Inc yet.
DiaMedica Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a r…
Full company profileDiaMedica Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DiaMedica Therapeutics Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 500K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -2.21K | -4.00K | 500K | -21.0K | -21.0K | -24.0K | -25.0K | -30.0K | -39.0K | - | - |
| Operating Income | -2.48M | -4.52M | -6.76M | -11.6M | -12.7M | -13.6M | -14.0M | -21.3M | -26.7M | -34.4M | -43.0M |
| EBITDA | -2.15M | -4.26M | -5.64M | -11.6M | -12.7M | -13.5M | -13.6M | -19.3M | -24.4M | -32.7M | -41.9M |
| Net Income | -2.22M | -4.26M | -5.73M | -10.6M | -12.3M | -13.6M | -13.7M | -19.4M | -24.4M | -32.8M | -42.0M |
| EPS | -0.47 | -0.72 | -0.74 | -0.89 | -0.78 | -0.65 | -0.52 | -0.60 | -0.60 | -0.70 | -0.78 |
| Balance Sheet | |||||||||||
| Total Assets | 1.87M | 1.80M | 18.3M | 9.05M | 28.1M | 45.6M | 34.4M | 54.2M | 46.3M | 61.4M | 36.2M |
| Total Liabilities | 627K | 1.00M | 1.31M | 1.44M | 2.08M | 1.53M | 2.57M | 3.10M | 5.63M | 5.26M | 7.49M |
| Shareholders' Equity | 1.25M | 799K | 17.0M | 7.62M | 26.0M | 44.0M | 31.8M | 51.1M | 40.7M | 56.1M | 28.7M |
| Cash & Short-term Investments | 1.74M | 1.35M | 16.8M | 7.88M | 27.5M | 45.1M | 33.5M | 52.9M | 44.1M | 59.9M | 34.9M |
| Total Debt | 200K | - | 23.0K | 178K | 118K | 52.0K | 469K | 400K | 340K | 240K | 157K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.02M | -3.90M | -5.70M | -9.10M | -9.19M | -12.3M | -11.5M | -18.7M | -22.1M | -29.1M | -34.7M |
| Capital Expenditure | 6.89K | 22.0K | 50.0K | 2.00K | 47.0K | 22.0K | 81.0K | 24.0K | 25.0K | 40.0K | 28.0K |
| Free Cash Flow | -3.03M | -3.92M | -5.75M | -9.10M | -9.23M | -12.3M | -11.6M | -18.8M | -22.1M | -29.1M | -34.7M |
| Ratios | |||||||||||
| ROE | -178.4% | -533.2% | -33.7% | -139.8% | -47.3% | -30.9% | -43.0% | -38.0% | -60.0% | -58.4% | -146.5% |
| ROA | -118.7% | -236.4% | -31.3% | -117.6% | -43.8% | -29.8% | -39.8% | -35.8% | -52.7% | -53.4% | -116.1% |
| Net Profit Margin | - | - | -1,146.8% | - | - | - | - | - | - | - | - |
| Debt to Equity | 0.16x | - | 0.00x | 0.02x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.00x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
DiaMedica Therapeutics Inc dividends
DiaMedica Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Nov 15, 2018.
Who owns DiaMedica Therapeutics Inc
- Insiders 27.83%
- Institutions 40.97%
- Public & others 31.20%
- Shares outstanding 53.9M
- Free float 25.3M
Top funds holding DMAC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 913K | 1.69% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 400K | 0.74% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 348K | 0.65% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 214K | 0.40% | +1.77% | Sep 2026 |
| Fidelity Extended Market Index | 147K | 0.27% | -5.12% | Sep 2026 |
| iShares Micro-Cap ETF | 111K | 0.21% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 88.4K | 0.16% | 0.00% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 68.0K | 0.13% | -9.99% | Sep 2026 |
| Fidelity Total Market Index | 60.7K | 0.11% | -0.05% | Sep 2026 |
| Jacob Discovery Fd Instl | 59.7K | 0.11% | -10.49% | Jun 2026 |
| Nuveen Small Cap Blend Idx R6 | 48.3K | 0.09% | 0.00% | Aug 2026 |
| Fidelity Series Total Market Index | 48.1K | 0.09% | 0.00% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 43.0K | 0.08% | -6.52% | Sep 2026 |
| Jacob Innovation Investor | 41.0K | 0.08% | 0.00% | Jun 2026 |
| Vanguard Russell 2000 Growth ETF | 40.5K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth Index | 36.6K | 0.07% | +5.84% | Aug 2026 |
| EQ/2000 Managed Volatility IB | 36.5K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 33.3K | 0.06% | 0.00% | Aug 2026 |
| Xtrackers Russell 2000 ETF 1C | 31.4K | 0.06% | -6.31% | Sep 2026 |
Top institutions holding DMAC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Cooperman Leon G | 3.45M | 6.40% | +70.79% | Jun 2026 |
| BlackRock Inc | 2.25M | 4.18% | +21.34% | Jun 2026 |
| Geode Capital Management, LLC | 894K | 1.66% | +14.55% | Jun 2026 |
| Millennium Management LLC | 845K | 1.57% | -9.65% | Jun 2026 |
| State Street Corp | 647K | 1.20% | +0.39% | Jun 2026 |
| Bleichroeder LP | 382K | 0.71% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 356K | 0.66% | +6.62% | Jun 2026 |
| Advisor Group Holdings, Inc. | 338K | 0.63% | +5.77% | Jun 2026 |
| Northern Trust Corp | 328K | 0.61% | -3.25% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 252K | 0.47% | +23.70% | Jun 2026 |
| LPL Financial Corp | 234K | 0.43% | +3.30% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 207K | 0.38% | +10.50% | Jun 2026 |
| The Goldman Sachs Group Inc | 168K | 0.31% | +183.47% | Jun 2026 |
| Citadel Advisors Llc | 146K | 0.27% | +0.10% | Jun 2026 |
| Squarepoint Ops LLC | 145K | 0.27% | 0.00% | Jun 2026 |
| Bank of New York Mellon Corp | 118K | 0.22% | +6.07% | Jun 2026 |
| MEMBERS WEALTH LLC | 101K | 0.19% | 0.00% | Jun 2026 |
| Charles Schwab Investment Management Inc | 96.7K | 0.18% | +9.35% | Jun 2026 |
| Cobalt Capital Management Inc | 90.0K | 0.17% | 0.00% | Jun 2026 |
| Trexquant Investment LP | 84.6K | 0.16% | +280.25% | Jun 2026 |
DiaMedica Therapeutics Inc company profile
- Company name
- DiaMedica Therapeutics Inc
- Ticker
- DMAC.US
- ISIN
- CA25253X2077
- Exchange
- USA Stocks
- Listed since
- Jan 4, 2008
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 35
- Fiscal year end
- December
- Address
- 301 Carlson Parkway, Minneapolis, MN, United States, 55305
- Phone
- 763 496 5454
- Website
- diamedica.com
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DiaMedica Therapeutics Inc management
5- Mr. Dietrich John Pauls MBAPresident, CEO & Director · born 1971
- Mr. Scott Kellen CPACFO & Corporate Secretary · born 1965
- Dr. Julie Krop M.D.Chief Medical Officer · born 1966
- Dr. Ambarish Shah Ph.D.Chief Technology Officer
- Mr. Dominic R. CundariChief Commercial Officer · born 1951